1. Search Result
Search Result
Isoforms Recommended: PPARβ/δ
Results for "

PPARβ

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13928
    GW0742
    Maximum Cited Publications
    18 Publications Verification

    GW610742

    PPAR Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742
  • HY-12377
    GSK0660
    10+ Cited Publications

    PPAR Metabolic Disease
    GSK0660 is a potent PPARβ antagonist with an IC50 of 155 nM.
    GSK0660
  • HY-N1029
    Norathyriol
    3 Publications Verification

    Mangiferitin

    Glycosidase PPAR Infection Inflammation/Immunology Cancer
    Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC50 of 3.12 μM . Norathyriol inhibits PPARα, PPARβ, and PPARγ with IC50s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.
    Norathyriol
  • HY-100277
    Mifobate
    1 Publications Verification

    SR-202

    PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate
  • HY-19383
    Ertiprotafib
    2 Publications Verification

    PTP 112

    Phosphatase IKK PPAR Metabolic Disease
    Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
    Ertiprotafib
  • HY-108571

    PPAR Cardiovascular Disease Metabolic Disease
    CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .
    CP-775146
  • HY-13928R

    GW610742 (Standard)

    PPAR Reference Standards Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742 (Standard)
  • HY-12377R

    PPAR Metabolic Disease
    GSK0660 (Standard) is the analytical standard of GSK0660. This product is intended for research and analytical applications. GSK0660 is a potent PPARβ antagonist with an IC50 of 155 nM.
    GSK0660 (Standard)
  • HY-101637

    JT 501

    PPAR Metabolic Disease
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
    Reglitazar
  • HY-116699

    PPAR Neurological Disease Metabolic Disease Inflammation/Immunology
    CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions .
    CP-868388 free base
  • HY-100277R

    SR-202 (Standard)

    Reference Standards PPAR Metabolic Disease
    Mifobate (Standard) is the analytical standard of Mifobate. This product is intended for research and analytical applications. Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: